Retail Equity Research

UPL Limited

ACCUMULATE

24th December, 2025 Sector: Chemicals

Key Chang	_{jes} Target		Rating	Ea	arnings	Target	Rs. 879
Stock Type	Bloomberg Code	Sensex	NSE Code	BSE Code	Time Frame	CMP	Rs. 781
Mid Cap	UPLL:IN	85,525	UPL	512070	12 Months	Return	+13%

Data as of: 23-12-2025 17:00 hrs

Data as 01. 23-12-202	0, 17100 1110					
Company Data						
Market Cap (Rs.cr)			65,938			
52 Week High — Lov	52 Week High — Low (Rs.) 78					
Enterprise Value (Rs.	cr)		94,282			
Outstanding Shares (cr)		84.4			
Free Float (%)			66.2			
Dividend Yield (%)			0.8			
6m average volume (cr) 0.25						
Beta			0.9			
Face value (Rs.)			2.0			
Shareholding (%)	Q4FY25	Q1FY26	Q2FY26			
Promoters	33.5	33.5	33.5			
FII's	37.2	37.8	39.9			
MFs/Institutions	18.6	18.1	17.2			
Public	9.0	8.7	7.8			
Others	1.7	1.9	1.7			
Total	100.0	100.0	100.0			
Promoter Pledge	Nil	Nil	Nil			
Price Performance	3 Month	6 Month	1 Year			

11.1% over or under performance to benchmark index

15.3%

4.2%

4.4%

17.8%

Absolute Return

Absolute Sensex

Relative Return



Y.E March (cr)	FY25A	FY26E	FY27E
Sales	46,637	50,512	54,814
Growth (%)	8.2	8.3	8.5
EBITDA	8,120	9,009	10,329
EBITDA Margin (%)	17.4	17.8	18.8
PAT Adjusted	1,305	2,233	3,536
Growth (%)	-175.5	65.3	95.7
Adjusted EPS	15.5	26.4	41.9
Growth (%)	-167.1	65.3	95.7
P/E	41.2	29.5	18.6
P/B	1.8	2.1	2.0
EV/EBITDA	9.5	10.5	9.0
ROE (%)	2.8	7.0	11.8
D/E	0.7	0.6	0.6

Growth revives as platform, mix and costs align

UPL Ltd is a global agriculture solutions company engaged in the agrochemicals and industrial chemicals business, with manufacturing sites globally. Through recent expansion, the company has become a leader in global food systems as well.

- UPL reported an 8.4% YoY growth in consolidated revenue in Q2FY26 to Rs. 12,019cr, driven by a 7.0% increase in volumes, primarily led by North America and supported by Latin America, as well as a 3.0% positive impact from exchange
- Agro segment revenue increased 8.0% YoY to Rs. 11,412cr in Q2FY26, while the non-Agro segment revenue grew 9.3% to Rs. 655cr.
- EBITDA surged 40.0% YoY to Rs. 2,205cr, with the margin expanding a significant 410bps YoY to 18.3%, supported by higher volume, an accretive product mix and lower raw-material cost.
- The company reported a profit after tax (PAT) of Rs. 612cr in Q2FY26, compared with a loss of Rs. 585cr in Q2FY25. This improvement was driven by lower net finance costs, controlled SG&A spending and reduced foreign exchange losses.

Outlook & Valuation

53.7%

8.9%

44.8%

UPL's strong Q2FY26 performance was characterised by broad-based operational improvement and margin accretion. With volume driving growth in both Global Protection and Advanta, the company enters H2FY26 with a healthier demand backdrop, normalised channel inventories and improved cost competitiveness. Management highlighted sustained traction in herbicidies and fungicidies, Advanta's integration with the post-harvest business continues to accelerate synergy benefits, and Superform's rising share of speciality chemicals strengthens diversification. Meanwhile, financial discipline remains a central theme, supported by improved working-capital efficiency and controlled finance costs. Therefore, we reiterate our ACCUMULATE rating on the stock, with a revised target price of Rs. 879 based on 21x FY27E adjusted EPS.

Quarterly Financials Consolidated

Rs.cr	Q2FY26	Q2FY25	YoY (%)	Q1FY26	QoQ (%)	H1FY26	H1FY25	YoY (%)
Sales	12,019	11,090	8.4	9,216	30.4	21,235	20,157	5.3
EBITDA	2,205	1,575	40.0	1,303	69.2	3,508	2,721	28.9
Margin (%)	18.3	14.2	410bps	14.1	420bps	16.5	13.5	300bps
EBIT	1,434	878	63.3	572	150.7	2,006	1,364	47.1
PBT	784	-447	n.m.	-190	n.m.	594	-902	n.m.
Rep. PAT	612	-585	n.m.	-176	n.m.	436	-1,112	n.m.
Adj PAT	411	-435	n.m.	-79	n.m.	332	-770	n.m.
Adj. EPS (Rs)	4.9	-5.8	n.m.	-0.9	n.m.	3.9	-10.3	n.m.



Key concall highlights

- The company successfully completed the final call of its right issue in September, receiving Rs. 1,685cr from shareholders.
- Management reported that North America saw a 79.0% YoY increase in revenue and Latin America reported a 10.0% YoY increase in Q2FY26. In Europe, revenue decreased 1% due to the normalisation of fungicide sales following a wet season in the previous year. The Rest of the World (ROW) markets reported a 10.0% revenue growth.
- All three global rating agencies—S&P, Fitch and Moody's—revised UPL's outlook from negative to stable during the quarter.
- Advanta platform reported a 26.0% YoY revenue growth, reaching Rs. 1,669cr, primarily driven by a 14.0% volume expansion in the
 seeds segment. Additionally, the Super Specialty business (SSC) saw an 18.0% increase in revenue, largely attributed to volume growth,
 with contribution from contract manufacturing.
- Management indicated that the FY26 organic capex remain in the range of \$200-225 million, split between tangible and intangible assets.
- The company expects growth in H2FY26 to be volume-driven, with prices expected to be roughly flat, and is confident about its positive
 momentum continuing through the second half of the year. This is supported by a strong product pipeline, with good results from products launched in the 1HFY26, especially in Latin America






EBIT



EBITDA



PAT



Change in Estimates

	Old estin	nates	New est	imates	Chanç	je (%)
Year / Rs cr	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Revenue	50,490	54,742	50,512	54,814	0.0	0.1
EBITDA	9,241	10,519	9,009	10,329	-2.5	-1.8
Margins (%)	18.3	19.2	17.8	18.8	-50bps	-40bps
Adj. PAT	2,574	3,655	2,233	3,536	-13.2	-3.3
EPS	30.5	43.3	26.4	41.9	-13.2	-3.3



Consolidated Financials

Profit & Loss

Y.E March (Rs. Cr)	FY23A	FY24A	FY25A	FY26E	FY27E
Sales	53,576	43,098	46,637	50,512	54,814
% change	15.9	-19.6	8.2	8.3	8.5
EBITDA	11,160	5,515	8,120	9,009	10,329
% change	9.8	-50.6	47.2	10.9	14.7
Depreciation	2,547	2,763	2,750	2,976	3,192
EBIT	8,613	2,752	5,370	6,033	7,137
Interest	2,963	3,852	3,627	3,518	3,377
Other Income	-500	-987	-914	123	1,086
PBT	5,150	-2,087	829	2,638	4,845
% change	3.7	-140.5	-139.7	218.2	83.7
Tax	736	-209	9	475	872
Tax Rate (%)	14.3	10.0	1.1	18.0	18.0
Reported PAT	4,414	-1,878	820	2,163	3,973
PAT att. to com- mon sharehold- ers	3,570	-1,200	897	2,366	3,536
Adj.*	170	252	408	-133	-
Adj. PAT	3,740	-948	1,305	2,233	3,536
% change	<i>-3.7</i>	-135.5	-175.5	65.3	95.7
No. of shares (cr)	78.0	75.1	84.4	84.4	84.4
Adj EPS (Rs.)	48.0	-12.6	15.5	26.4	41.9
% change	-2.4	-136.8	-167.1	65.3	95.7
DPS (Rs.)	10.0	1.0	6.0	8.4	9.6

Balance Sheet

Y.E March (Rs. Cr)	FY23A	FY24A	FY25A	FY26E	FY27E
Cash	6,097	6,036	9,537	4,069	5,364
Accts. Receivable	18,224	16,354	15,505	16,694	18,006
Inventories	13,985	12,776	10,316	13,991	14,200
Other Cur. Assets	3,722	4,162	4,303	3,653	3,433
Investments	1,569	1,893	2,008	2,178	2,351
Gross Fixed Assets	15,248	16,358	16,731	18,600	20,601
Net Fixed Assets	8,164	8,443	8,107	6,988	5,784
CWIP	1,197	1,106	615	627	640
Intangible Assets	32,170	32,472	32,908	34,500	35,645
Def. Tax -Net	2,661	3,595	3,322	3,850	3,927
Other Assets	788	709	1,381	1,988	2,622
Total Assets	88,577	87,546	88,002	88,539	91,974
Current Liabilities	26,182	22,433	23,118	22,791	23,095
Provisions	217	386	335	385	424
Debt Funds	24,287	29,615	24,733	24,003	23,853
Other Liabilities	2,462	2,406	1,990	2,070	2,152
Equity Capital	150	150	159	169	169
Res. & Surplus	26,708	24,657	29,054	30,711	33,433
Shareholder Funds	26,858	24,807	29,213	30,880	33,602
Minority Interest	8,571	7,899	8,613	8,410	8,847
Total Liabilities	88,577	87,546	88,002	88,539	91,974
BVPS	344	330	346	366	398

Cashflow


Y.E March (Rs. Cr)	FY23A	FY24A	FY25A	FY26E	FY27E
Net inc. + Depn.	6,961	885	3,570	5,139	7,165
Non-cash adj.	3,677	2,330	2,961	-762	-578
Other adjustments	-	-	-	-	-
Changes in W.C	-2,887	-894	3,620	-4,235	-451
C.F. Operation	7,751	2,321	10,151	142	6,135
Capital exp.	-2,289	-1,954	-1,255	-3,461	-3,147
Change in inv.	432	-970	-922	-100	-100
Other invest.CF	367	446	337	-1,600	-830
C.F - Investment	-1,490	-2,478	-1,840	-5,161	-4,077
Issue of equity	705	-	1,633	10	-
Issue/repay debt	-4,595	4,805	-5,354	250	50
Dividends paid	-750	-749	-77	-710	-813
Other finance.CF	-1,587	-3,892	-995	-	-
C.F - Finance	-6,227	164	-4,793	-450	-763
Chg. in cash	34	7	3,518	-5,468	1,296
Closing Cash	6,097	6,036	9,537	4,069	5,364

Ratio

Y.E March	FY23A	FY24A	FY25A	FY26E	FY27E
Profitab. & Return					
EBITDA margin (%)	20.8	12.8	17.4	17.8	18.8
EBIT margin (%)	16.1	6.4	11.5	11.9	13.0
Net profit mgn.(%)	8.2	-4.4	1.8	4.3	7.2
ROE (%)	16.4	-7.6	2.8	7.0	11.8
ROCE (%)	14.4	4.4	8.6	9.5	10.8
W.C & Liquidity					
Receivables (days)	124.2	138.5	121.3	120.6	119.9
Inventory (days)	187.1	190.4	155.4	200.2	187.8
Payables (days)	235.7	188.2	163.7	164.5	166.2
Current ratio (x)	1.4	1.5	1.4	1.3	1.4
Quick ratio (x)	8.0	8.0	0.9	0.7	8.0
Turnover &Leverage					
Gross asset T.O (x)	3.7	2.7	2.8	2.9	2.8
Total asset T.O (x)	0.6	0.5	0.5	0.6	0.6
Int. covge. ratio (x)	2.9	0.7	1.5	1.7	2.1
Adj. debt/equity (x)	0.7	0.9	0.7	0.6	0.6
Valuation					
EV/Sales (x)	1.5	1.5	1.7	1.9	1.7
EV/EBITDA (x)	7.4	11.9	9.5	10.5	9.0
P/E (x)	15.0	n.m.	41.2	29.5	18.6
P/BV (x)	2.1	1.4	1.8	2.1	2.0



Recommendation Summary -(Last 3 years)



Dates	Rating	Target
03-Feb-22	BUY	884
05-Aug-22	BUY	880
16-May-23	HOLD	739
05-Aug-23	HOLD	643
27-May-24	HOLD	555
21-Aug-24	ACCUMULATE	640
05-Jun-25	ACCUMULATE	736
24-Dec-25	ACCUMULATE	879

Investment Rating Criteria

Ratings	Large caps	Midcaps	Small Caps
Buy	Upside is above 10%	Upside is above 15%	Upside is above 20%
Accumulate	-	Upside is between 10%-15%	Upside is between 10%-20%
Hold	Upside is between 0% - 10%	Upside is between 0%-10%	Upside is between 0%-10%
Reduce/sell	Downside is more than 0%	Downside is more than 0%	Downside is more than 0%

Not rated/Neutral

Buy: Acquire at Current Market Price (CMP), with the target mentioned in the research note; Accumulate: Partial buying or to accumulate as CMP dips in the future; Hold: Hold the stock with the expected target mentioned in the note.; Reduce: Reduce your exposure to the stock due to limited upside.; Sell: Exit from the stock; Not rated/Neutral: The analyst has no investment opinion on the stock.

Symbols definition:







Downgrade

To satisfy regulatory requirements, we attribute 'Accumulate' as Buy and 'Reduce' as Sell.

The recommendations are based on 12 month horizon, unless otherwise specified. The investment ratings are on absolute positive/negative return basis. It is possible that due to volatile price fluctuation in the near to medium term, there could be a temporary mismatch to rating. For reasons of valuations/ return/lack of clarity/event we may revisit rating at appropriate time. Please note that the stock always carries the risk of being upgraded to BUY or downgraded to a HOLD, REDUCE or SELL.

Not rated/Neutral- The analyst has no investment opinion on the stock under review.

Certification: I, ANIL R, author of this Report, hereby certify that all the views expressed in this research report reflect our personal views about any or all of the subject issuer or securities. This report has been prepared by the Research Team of Geojit Investments Limited, hereinafter referred to as GIL. For general disclosures and disclaimer: Please Click here

CRIŠIL has provided research support in preparation of this research report and the investment rational contained herein along with financial forecast. The target price and recommendation provided in the report are strictly GIL's views and are NOT PROVIDED by CRISIL. Further, CRISIL expresses no opinion on valuation and the associated recommendations. CRISIL has no financial liability whatsoever, to the subscribers / users of this report.

Regulatory Disclosures:

Group companies/ Fellow subsidiaries of Geojit Investments Ltd (GIL) are Geojit Financial Services Limited (GFSL), Geojit Technologies Private Limited (Software Solutions provider), Geojit Credits Private Limited (NBFC), Geojit Fintech Private Ltd, Geojit IFSC Ltd (a company incorporated under IFSC Regulations), Qurum Business Group Geojit Securities LLC (a subsidiary of holding company in Oman engaged in Financial Services), Barjeel Geojit Financial Services LLC (a joint venture of holding company in UAE engaged in Financial Services), and BBK Geojit Consultancy and Information KSC (C) (a joint venture in Kuwait-engaged in Financial services). In the context of the SEBI Regulations on Research Analysts (2014), GIL affirms that we are a SEBI registered Research Entity and in the course of our business as a stock market intermediary, we issue research reports /research analysis etc. that are prepared by our Research Analysts. We also affirm and undertake that no disciplinary action has been taken against us or our Analysts in connection with our business activities. In compliance with the above-mentioned SEBI Regulations, the following additional disclosures are also provided which may be considered by the reader before making an investment

decision:

1. Disclosures regarding Ownership:

GIL confirms that:

(i)It/its associates have no financial interest or any other material conflict in relation to the subject company (ies) covered herein, at the time of publication of the research report. (iii)It/its associates have no actual beneficial ownership of 1% or more in relation to the subject company (ies) covered herein, at the end of the month immediately preceding the date of publication of the research report.

Further, the Analyst confirms that:

- (i) He, his associates and his relatives shall take reasonable care to ensure that they do not have any financial interest in the subject company (ies) covered herein, and they have no other material conflict in the subject company, at the time of publication of the research report.

 (ii) He, his associates and his relatives have no actual/beneficial ownership of 1% or more in the subject company covered, at the end of the month immediately preceding the date of
- publication of the research report.

2. Disclosures regarding Compensation:
During the past 12 months, GIL or its Associates:

(a) Have not received any compensation from the subject company; (b) Have not managed or co-managed public offering of securities for the subject company (c) Have not received any compensation for investment banking or merchant banking or brokerage services from the subject company. (d) Have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company. e) Have not received any compensation or other benefits from the subject company or third party in connection with the research report (f) The subject company is / was not a client during twelve months preceding the date of distribution of the research report.

3. Disclosure by GIL regarding the compensation paid to its Research Analyst:

GIL hereby confirms that no part of the compensation paid to the persons employed by it as Research Analysts is based on any specific brokerage services or transactions pertaining to

- trading in securities of companies contained in the Research Reports
- 4. Disclosure regarding the Research Analyst's connection with the subject company: It is affirmed that I, ANIL R, Research Analyst (s) of GIL have not served as an officer, director or employee of the subject company.

5. Disclosure regarding Market Making activity: Neither GIL/its Analysts have engaged in market making activities for the subject company.

- 6. Disclosure regarding conflict of interests: GIL shall abide by the applicable regulations/ circulars/ directions specified by SEBI and Research Analyst Administration and Supervisory Body (RAASB) from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. GIL will endeavour to promptly inform the client of any conflict of
- The contract of the services being rendered to the client.

 7. "Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."

8. Clients are required to keep contact details, including email id and mobile number/s updated with the GIL at all times.

- 9. In the course of providing research services by GIL, GIL cannot execute/carry out any trade (purchase/sell transaction) on behalf of, the client. Thus, the clients are advised not to permit GIL to execute any trade on their behalf.
- 10. GIL will never ask for the client's login credentials and OTPs for the client's Trading Account Demat Account and Bank Account. The Clients are advised not to share such information with anyone including GIL.

11.Standard Warning: "Investment in securities market are subject to market risks. Read all the related documents carefully be-

12. Disclosures regarding Artificial Intelligence tools: Neither Geojit Investments Limited nor its Analysts have utilized any AI tools in the preparation of the research reports.

Please ensure that you have read the "Risk Disclosure Documents for Capital Market and Derivatives Segments" as prescribed by the Securities and Exchange Board of India before investina.

Geojit Investments Ltd. Registered Office: 7th Floor 34/659-P, Civil Line Road, Padivattom, Kochi-682024, Kerala, India. Phone: +91 484-2901000, Website: www.geojit.com/GIL. For investor queries: customercare@geojit.com

GRIEVANCES

Step 1: The client should first contact the RA using the details on its website or following

contact details: Compliance officer: Ms. Indu K. Address: 7th Floor, 34/659-P, Civil Line Road, Padivattom, Ernakulam,; Phone: +91 484-2901367; Email: compliance@geojit.com. For Grievances: grievances@geojit.com. Step 2: If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at www.scores.sebi.gov.in Step 3: The client may also consider the Online Dispute Resolution (ODR) through the Smart ODR portal at https://smartodr.in

Corporate Identity Number: U66110KL2023PLC080586, Research Entity SEBI Reg No: INH000019567; Depository Participant: IN-DP-781-2024.